Background: Small cell carcinoma of the ovary hypercalcemic type (SCCOHT) is a rare tumor with a peak incidence in young adulthood that historically has carried a poor prognosis.
S mall cell carcinoma of the ovary hypercalcemic type (SCCOHT) is a rare tumor with a historically poor survival. SCCOHT is characterized by small cells with neuroendocrine differentiation, although tumors may be comprised of large cells. Approximately, two thirds of patients present with hypercalcemia, which is thought to represent a paraneoplastic phenomenon. A 1993 retrospective review of 150 SCCOHT cases documented that only 14 of 42 evaluable stage IA patients were alive without disease at an average follow-up period of 5.7 years. 1 The prognosis for more advanced stage disease was found to be dismal. [1] [2] [3] However, more recent reports, some including pediatric cases, have demonstrated that SCCOHT is a potentially curable disease even in advanced stages. [4] [5] [6] [7] We report 2 preadolescent patients with advanced stage disease treated with cisplatin-based chemotherapy and surgical resection. The first patient underwent a gross total resection of tumor at diagnosis. Because of the presence of bulky tumor mass at initiation of therapy and the finding of residual viable tumor after neoadjuvant chemotherapy, the therapy of the second patient was consolidated with high-dose chemotherapy with stem cell rescue (HD-SCR) and external beam radiation. The tumor derived from the latter patient expressed VEGF, providing a rationale for maintenance therapy with bevacizumab. The first patient is likely cured of disease 7 years after diagnosis. The other patient is free of disease 33 months after diagnosis. Our experience demonstrates that advanced stage SCCOHT in children is curable.
PATIENT 1
A 10-year-old female presented with a history of nausea, abdominal pain, and dysuria. Computed tomography (CT) demonstrated a 14 cm pelvic mass with solid and cystic components (Fig. 1) . Her tanner staging was 3 (pubic hair) and 2 (breast). Her calcium was elevated at 12.3 mg/dL (reference range, 8.9 to 10.1 mg/dL) but parathyroid hormone was <10 pg/mL. LDH was 1264 U/L (range, 380 to 700 U/L) and uric acid was 5.8 mg/dL (range, 3.0 to 4.7 mg/dL). AFP and b-HCG were normal. She underwent an exploratory laparotomy that included a complete resection of the ruptured right ovarian tumor. Systematic surgical tumor staging was undertaken with no evidence of tumor noted upon inspection of the contralateral ovary, pelvic lymph nodes, or peritoneum. In addition to the primary ovarian mass, evidence of SCCOHT was identified through sampling of omentum and enlarged juxtarenal vena caval lymph nodes (Fig. 2) . Cytology of peritoneal fluid was also positive for malignant disease. There was no evidence of pulmonary metastatic disease on CT of the chest. International Federation of Gynecology and Obstetrics (FIGO) tumor stage was IIIC. 8 The patient was treated with a chemotherapy regimen consisting of 6 cycles of vinblastine (6 mg/m (VPCBAE) every 3 to 4 weeks. She completed therapy 5 months after diagnosis with adverse effects that included myelosuppression, febrile neutropenia, anorexia, and hypomagnesemia. She is now free of disease 7 years after completing therapy.
PATIENT 2
A 6-year-old prepubescent female was referred to the treating institution after undergoing a partial surgical resection of a pelvic mass at an outside hospital. She initially presented with bilateral leg pain and weight loss. A palpable 9 cm mass was visualized by magnetic resonance imaging of the pelvis (Fig. 1) . At the time of the initial surgical procedure, the mass was found to be ruptured. Pathologic review confirmed the diagnosis of SCCOHT, large cell variant (Fig. 3) . Immunohistochemistry (IHC) demonstrated diffuse cytoplasmic immunoreactivity of VEGF (3 +) in the tumor cells. The IHC stain for c-KIT (CD117) was negative (PhenoPath Laboratories, Seattle, WA) (Fig. 3) . The CT of chest and technetium bone scan demonstrated no distant metastatic disease. AFP, b-HCG, CEA, and CA 19-9 were normal. Calcium was normal.
Complete blood count showed normocytic anemia (Hb 8.7 mg/dL) and thrombocytosis (1.2Â10 6 /mL). Fluorodeoxyglucose positron emission tomography scan revealed faintly increased metabolic activity at the site of the residual tumor only. FIGO tumor stage was IIIB based on evidence of peritoneal metastases but none documented to be >2 cm in diameter.
At arrival to the treating institution the patient was shown to have recurrent massive tumor burden (Fig. 1) . Rather than undertake another upfront surgical resection, the patient was treated with neoadjuvant chemotherapy consisting of VPCBAE. Hematopoietic stem cells were successfully collected after the second cycle of chemotherapy. The patient underwent 2 additional surgeries. After the fourth cycle of chemotherapy, an exploratory laparotomy was undertaken that included a right iliac lymph node dissection and right salpingo-oophorectomy. Biopsies were taken of the left ovary and tumor implants on the peritoneum, small bowel, uterus, and bladder. Only the implant adherent to the uterus revealed viable tumor tissue. A final surgery was undertaken after the sixth cycle of chemotherapy to resect a regressing but viable retroperitoneal tumor mass. Because of the finding of viable tumor within the mass, a hysterectomy and left salpingo-oophorectomy were deemed necessary to render the patient a complete remission (CR). Given the finding of chemosensitive disease but persistent viable tumor after conventional chemotherapy dosing VPCBAE, her therapy was consolidated with a HD-SCR regimen consisting of carboplatin, etoposide, and melphalan conditioning. Complications of VPCBAE therapy included myelosuppression, febrile neutropenia, and anorexia. Adverse effects experienced during HD-SCR included hepatic sinusoidal obstruction syndrome with nonmalignant ascites leading to abdominal compartment syndrome manifested by renal insufficiency and respiratory failure. After recovery, the patient underwent external beam radiotherapy, initially receiving 22.5 Gy to the whole abdomen and pelvis using intensity modulation radiation therapy technique. The liver was blocked and the abdomen and pelvis were treated with another 7.5 Gy. The pelvis was then treated with an additional 19.8 Gy. The patient received a maintenance course of bevacizumab at doses of 5 or 10 mg/kg every 2 weeks for 6 months. The dose was titrated based on the severity of grade 1 to 2 diarrhea that was attributed to bevacizumab (Common Terminology Criteria for Adverse Events version 4.0). She is now free of disease 33 months after diagnosis.
DISCUSSION
SCCOHT is a rare tumor type that often presents in advanced stages. The incidence of SCCOHT is uncertain but approximately 400 patients have been previously reported. 9 In the retrospective series reported by Young and colleagues, the patient age range was 7 to 43 years with a mean age of 24, documenting that this is primarily a disease of young women and adolescents. The youngest patient reported to date was a 14-month-old. 10 At 10 and 6 years of age at diagnosis, the patients in the present study are among the youngest reported. Whether tumors derived from preadolescent SCCOHT patients differ clinically or biologically from other SCCOHT tumors is not known. The experience reported here confirms that SCCOHT is responsive to therapy. Patient 1 has now experienced a durable long-term remission and is considered cured of her disease. Successfully treated patients have typically undergone surgical resection and received cisplatin-based chemotherapy. 6 Surgery seems to be of critical importance, although the appropriate timing and necessary extent of tumor resection are not well defined. When feasible, upfront surgical tumor removal has been advocated to facilitate the effectiveness of chemotherapy. 5 Patient 2 originally underwent a gross tumor resection at diagnosis but presented to the treating institution with massive recurrent tumor burden before the initiation of therapy. Her remaining gross tumor mass continually regressed throughout her chemotherapeutic treatment, but further surgical resections were necessary to remove persistent viable tumor and achieve a CR. Hence, chemotherapy provided benefit and likely facilitated surgical resection but, alone, was not sufficient to treat bulky tumor. At 33 months from diagnosis, patient 2 remains free of disease. A retrospective review of 135 SCCOHT patients published in case reports and series found that 82 of 126 (65.1%) patients were reported to experience tumor recurrence. 11 The average time to recurrence was 11.5 months (SD 13.3 mo) with a range of 1 to 70 months. Given the lack of prospective data to guide patient follow-up, patient 2 is still considered to be at some risk of recurrence and will be monitored radiologically every 6 to 12 months until she is 5 years from the end of therapy. 1, 12 The importance of adjuvant chemotherapy is highlighted by the likelihood of relapse among low-stage patients treated with surgical resection only. 2,4 Senekjian et al 13 was the first to cite the use of VPCBAE therapy for SCCOHT in 1989. Four of 5 patients in the report experienced a CR with VPCBAE therapy and surgery with or without radiation; the other patient had a partial response. However, only 1 of the 5 patients had a long-term remission. More recently, VPCBAE has been successfully used in combination with surgery in stage II and III SCCOHT. [14] [15] [16] HD-SCR has been utilized as a consolidative therapy in several case reports and in a prospective trial. In the study by Pautier and colleagues, 7 of 10 patients in CR after surgery and cisplatin-containing chemotherapy who underwent HD-SCR remained in CR, compared with 3 of 8 patients treated without HD-SCR; although, there was a higher proportion of advanced stage patients in the latter group. The median follow-up was 37 months. 5 In 2 additional reports, 6 patients treated with HD-SCR as part of multimodal therapy have survived without evidence of disease with follow-up ranging from 7 months to 14 years. 4, 12 HD-SCR was utilized in patient 2 in the present report. The patient suffered severe toxicity but fully recovered and was able to rapidly proceed to radiation therapy.
Radiotherapy has not been routinely used in SCCOHT therapy, but there is limited information to suggest a potential benefit. Young et al 1 reported that 4 of 5 stage IA patients who received radiation, including 3 who received only adjuvant radiation without chemotherapy, did not experience recurrence. Two patients who experienced durable responses after radiation therapy alone after initial surgery were reported by Dickersin and colleagues. One patient was alive without evidence of disease 5 years after therapy. The other, who had peritoneal tumor implants at the time of initial surgery, relapsed 5 years after adjuvant radiation. 2 In order to augment local control measures, patient 2 in the present report was treated with radiation therapy with minimal short-term adverse effects.
The molecular biology underlying SCCOHT is poorly characterized. The identification of c-KIT expression was demonstrated in a tumor from a patient successfully treated with imatinib in combination with VPCBAE. 16 VEGF, but not c-KIT, expression was documented by IHC in tumor tissue from patient 2 in the present series, supporting the use of bevacizumab. A similar use of bevacizumab is suggested to be of benefit in adults with epithelial ovarian tumors. 17 The documentation of VEGF expression in the present case is a novel finding in SCCOHT. Further insight into the molecular alterations contributing to the genesis of SCCOHT will be necessary to identify innovative therapeutic approaches. Molecular characterization of SCCOHT may also shed light on potential distinctions between tumors developing in children versus those that arise in older patients. Other therapeutic strategies that may be useful include regional hyperthermia or hyperthermic intraperitoneal chemotherapy. 18 The former approach, along with multiagent chemotherapy and melphalan HD-SCR, has been reported in the treatment of a 16-year-old with stage IIIC SCCOHT. 4 Ultimately, systematic studies of pediatric and adult patients will need to be undertaken to define a SCCOHT standard of care and assess the utility of new approaches including antiangiogenesis agents such as monoclonal antibodies or multityrosine kinase inhibitors.
On the basis of published findings and the experience described above, the authors advocate that surgery and cisplatin-based chemotherapy form the foundation of SCCOHT therapy. As demonstrated by patient 1, this combination may be sufficient to adequately treat even advanced stage SCCOHT. Ideally, surgical resection would be undertaken at diagnosis, with resection of the primary mass, and sampling of the omentum, peritoneum, contralateral ovary, and other lesions similar to the approach taken in patient 1. Cisplatin-based therapy such as VPCBAE would be used to treat remaining gross tumor and distant micrometastases. On the basis of several reports, HD-SCR as consolidative therapy has been used in successfully treated patients. The role of radiation therapy is less clear. There are isolated cases of patients who seem to have responded to radiation alone after initial surgery. However, without stronger evidence to support its use, radiation should be reserved for augmented local control in patients that have not fully responded to surgery and chemotherapy, such as that experienced by patient 2.
